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Abstract
Background: The effect of centrifugation time of heparinized blood samples on clinical chemistry and
immunology results has rarely been studied. WHO guideline proposed a 15 min centrifugation time without citing
any scientific publications. The centrifugation time has a considerable impact on the turn-around-time.
Methods: We investigated 74 parameters in samples from 44 patients on a Roche Cobas 6000 system, to see
whether there was a statistical significant difference in the test results among specimens centrifuged at 2180 g for
15 min, at 2180 g for 10 min or at 1870 g for 7 min, respectively. Two tubes with different plasma separators (both
Greiner Bio-One) were used for each centrifugation condition. Statistical comparisons were made by Deming fit.
Results: Tubes with different separators showed identical results in all parameters. Likewise, excellent correlations
were found among tubes to which different centrifugation conditions were applied. Fifty percent of the slopes lay
between 0.99 and 1.01. Only 3.6 percent of the statistical tests results fell outside the significance level of p < 0.05,
which was less than the expected 5%. This suggests that the outliers are the result of random variation and the
large number of statistical tests performed. Further, we found that our data are sufficient not to miss a biased test
(beta error) with a probability of 0.10 to 0.05 in most parameters.
Conclusion: A centrifugation time of either 7 or 10 min provided identical test results compared to the time of 15
min as proposed by WHO under the conditions used in our study.
1. Background
Most clinical chemistry analyses in blood samples
require centrifugation prior to the analyses in order to
separate blood cells and other solid components such as
fibrin from serum or plasma. Although this pre-analyti-
cal procedure is performed innumerable times every day
in all medical laboratories worldwide, the influence of
centrifugation on laboratory results has only rarely and
only recently been investigated [1-3]. Indeed, the infor-
mation contained in the publications and guidelines
from scientific societies rely either on expert opinions or
recommendations from the manufacturers rather than
on published scientific investigations [4-6].
The separation efficacy of the centrifugation process
depends on four variables, the centrifugation time, the
relative centrifugation force (RCF), the length of blood
collection tubes and the temperature. The length of
tubes defines the volume of plasma or serum that is
required for the analyses and is usually given. The RCF
is limited by the resistance of the tubes and the blood
components to the gravity and the technical limits of
the centrifuge and its rotor. Variations in temperature
are limited by stability of analytes. Thus, only the centri-
fugation time can be easily varied to achieve the desired
quality of the specimen for the subsequent analyses.
The above cited guidelines proposed a centrifugation
time of at least 10 min for serum and of 15 min for
plasma with a RCF between 2000 and 3000 g [6]. Hospi-
tal laboratories serving emergency departments, inten-
sive care units and busy outpatient clinics strive for
minimizing their turn-around-times (TAT)[2]. The cen-
trifugation step consumes a large portion of the pre-
analytical time in the laboratory and therefore a consid-
erable amount of the total TAT. A reduction in this
time-consuming step is therefore in the focus. Indeed,
centrifugation times as short as 30 sec have been used
under certain circumstances, but no formal evaluations
of such procedures have been published [7,8].
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plasma instead of serum. Serum samples from fully
anticoagulated patients mayc o n t i n u et oc o a g u l a t ef o r
several hours after blood draw, which may affect the
analytical process. Small particles of fibrin clots may
block pipetting needles of the analyzers or interfere with
chemiluminescence assays. Although collection tubes
with special additives to reduce coagulation time to a
few minutes, have been developed [3], yet we found that
the coagulation process in specimens of fully anticoagu-
lated patients is not completed after 15 min (E. Minder,
unpublished observations). An alternative is to use tubes
containing lithium heparinate which prevents coagula-
tion and allows centrifugation immediately after the
arrival of the tubes in the laboratory. Heparinized
plasma instead of serum can be used for most clinical
chemistry and many immunological analyses today,
depending on the analytical platform and the reagents
used.
Gels, also called separators, interpose between the cel-
lular and fluid phase of the blood specimen during cen-
trifugation and act as a barrier thereafter preventing the
diffusion of analytes between the two phases. The gel
barrier is formed only after adequate centrifugation time
and force. An incomplete gel formation may interfere
with certain analyses [9]. Separator gels from different
manufacturers may have different compositions and
therefore behave differently under identical centrifuga-
tion conditions, which could results in differences in
test results.
In this report, we investigated the effect of distinct
centrifugation conditions on a broad range of routine
clinical chemistry and immunology analyses. These con-
ditions included the centrifugation time pro-posed by
the WHO-guidelines and two shorter ones of 10 and 7
min, respectively. We also examined the possible effect
of two different gel separators on the same set of labora-
tory parameters.
2. Methods
2.1 Patients
Consecutive patients admitted to our medical wards
between September and October 2009 were asked to
provide six additional tubes for the study during regular
blood draws. Exclusion criterion was a known or sus-
pected anemia.
2.2 Blood sampling and centrifugation
Phlebotomy was performed using a butterfly needle
(Greiner Bio-One reference number 450085). Between
the regular drawing and the study samples, a 5 ml Z no
additive Vacuette
® (Greiner Bio-One reference number
456202) was filled and discarded. Then, three evacuated
tubes with gel separator (5 ml Lithium Heparin Sep 13
× 100 mm Vacuette
® Premium, Greiner Bio-One refer-
ence number 456083, available in Europe, called ‘tube
11’ hereafter) and three evacuated tubes with gel separa-
tor (5 ml Lithium Heparin Sep 13 × 100 mm Vacuette
®,
Greiner Bio-One reference number 456087 RP, available
in USA, called ‘tube 22’ hereafter) were filled with
venous blood. After gently inverting the tubes eight
times, they were sent immediately to the laboratory by a
pneumatic tube system and centrifuged within one hour
after blood draw on a Rotixa 50 RS Hettich centrifuge
equipped with a swing-out bucket rotor. The three cen-
trifugation conditions were as follows: acceleration time
o f3 2s e c( i n c l u d e di nt h eo v e rall centrifugation time),
deceleration time of 32 sec (after centrifugation) and
temperature at +15°C in all three conditions; condition
1: centrifugation time 15 min at 2180 g or 32,700 gmin,
condition 2: 10 min at 2180 g or 21,800 gmin and con-
dition 3: 7 min at 1870 g or 13,090 gmin, respectively.
The sequence of the tubes during blood draw was
registered. To avoid any influence from this sequence, a
pre-specified randomization protocol was used to allo-
cate the tubes to the different centrifugation conditions.
A collection of samples from at least 40 patients would
attain sufficient statistical power and thus specimens
from 47 patients were collected. Analyses were per-
formed only if all six tubes collected per patient were of
sufficient quality, i.e. without visible hemolysis or lipide-
mia. Tubes from 44 patients met the criteria and were
therefore investigated. For statistical reasons, a patient
was included only once.
2.3 Analyses of samples
Certified medical technicians with several years of work-
ing experience performed all laboratory procedures.
Immediately after centrifugation, the samples were ana-
lyzed on a COBAS 6000 analyzer (Roche Diagnostics,
Rotkreuz, Switzerland) equipped with the core unit cu
150 (Part number 727-0189), the modules c 501 (part
number 727-2983) and e 601 (part number 727-2984).
The instrument was equipped with standard reagents,
calibrators and quality control material manufactured by
Roche Diagnostics (Rotkreuz, Switzerland). Seventy-four
different tests as listed in table 1 were performed on
each tube, giving rise to a total of 444 results per
patient. The analyses were performed within 3 hours
after the sample collection with an exception of the
immunological parameters for infectious diseases, which
were examined within 48 hours. All tubes were stored
at 4°C before analyses.
This study was initiated by the investigators; the costs
of the study were covered by two companies (see
acknowledgments). The study was approved by the insti-
tutional review board (Kantonale Ethikkommission Zür-
ich), and the participating patients gave their written
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Test Abbreviation QC
target
value
unit n mean SD CV Maximal
error
(CLIA)
lowest
measured
value
highest
measured
value
Range
Ratio
estimated beta-
error smaller
than
Federal
Register
Qualab Clinical
estimate
Albumin Alb 47 g/L 16 47.44 0.81 1.71 3.65 25 48 1.92 <10% ± 10% ± 15%
Alb 30.9 g/L 18 31.71 0.71 2.28
Alcaline
Phosphatase
AP 71.9 U/L 18 70.56 1.04 1.47 67.80 36 416 11.56 <5% ± 30% ± 21%
AP 210 U/L 13 207.53 3.39 1.63
Alanin
aminotransferase
ALTL 45.5 U/L 17 45.65 0.49 1.07 36.10 7 354 50.57 <5% ± 20% ± 21%
ALTL 126 U/L 19 126.47 1.58 1.25
Amikacin Amik 7.83 umol/L 9 8.822 1.057 11.98 0.28 0 2.8 UD! <10% 10%
Amik 23.1 umol/L 9 23.828 1.341 5.63
Amik 46.3 umol/L 11 48.225 2.994 6.2
Pancreatic Amylase Amy-P 40 U/L 18 39.83 0.71 1.78 19.88 2 157 78.50 <5% ± 25%
Amy-P 107 U/L 19 107.11 1.05 0.98
Amylase Amyl 79.5 U/L 16 79.31 0.79 1 29.25 13 182 14.00 <5% ± 30% ± 30%
Amyl 198 U/L 12 195.56 1.42 0.73
Aspartate
aminotransferase
ASTL 47.3 U/L 17 46.59 1.18 2.53 25.40 10 244 24.40 <5% ± 20% ± 21%
ASTL 152 U/L 19 15.063 3.18 2.11
Bili-D 28.1 umol/L 19 28.326 1.125 3.97 22.20 1.1 220.9 200.82 20%
Total Bilirubin Bili-T 16.5 umol/L 17 16.888 0.376 2.23 6.84 2.8 213.9 76.39 <5% ± 6.84 umol/
L or ± 20%
± 20%
Bili-T 76.3 umol/L 19 75.421 5.257 6.97
Calcium Ca 2.13 mmol/L 18 2.1233 0.0406 1.91 0.25 1.87 2.71 1.45 <10% ± 0.25 umol/L ± 12%
Ca 3.41 mmol/L 21 3.3681 0.0515 1.53
Carbamazepine Carb 13.6 umol/L 9 11.6 1.773 15.28 0.13 0 1 UD <5% ± 25%
Carb 37.9 umol/L 10 330.46 3.45 10.31
Carb 60.9 umol/L 11 54.955 4.377 7.96
Cholinesterase CHE 5400 U/L 16 5232.13 98.07 1.87 1216.80 2877 9291 3.23 <5% 20%
CHE 1340 U/L 18 1313.78 26.47 2.01
Cholesterol Chol 2.65 mmol/L 17 2.718 0.039 1.43 0.51 2.3 7.8 3.39 <10% ± 10% ± 10%
Cholesterol Chol 5.27 mmol/L 18 5.117 0.051 1
Creatinin Kinase CK 152 U/L 18 148.78 1.7 1.14 69.60 12 452 37.67 <5% ± 30% ± 30%
CK 499 U/L 18 494.56 6.29 1.27
CK, iso-enzyme MB CKMB 5.13 ng/mL 9 5.43 0.063 1.16 1.45 0.9 21.2 23.56 ? ±3S D
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5Table 1 All test analyzed, their control values and further data used for estimation of the beta error. (Continued)
CKMB 56.7 ng/mL 7 55.62 0.903 1.62
Bicarbonate CO2 18.1 mmol/L 17 18.575 0.331 1.78 2.08 10.3 31.3 3.04 <10% 10%
CO2 31.6 mmol/L 17 31.292 0.63 2.01
Cortisol Cort 300 nmol/L 16 312.6 10.22 3.27 190.83 110.6 1416 12.80 <5% ± 25% ± 20%
Cort 723 nmol/L 13 733.3 12.22 1.67
Creatinine Crea 89.1 umol/L 18 91.06 3.28 3.6 37.13 40 455 11.38 <5% ± 26.5 umol/L or ± 15%
Crea 346 umol/L 18 345.61 6.98 2.02
C-reactive Protein CRP 9.7 mg/L 15 9.653 0.223 2.31 16.26 0.3 216.5 721.67 <5% ± 21%
CRP 53.2 mg/L 16 52.706 2.088 3.96
Chloride Cl 84.8 mmol/L 28 83.709 2.623 3.13 5.15 87.9 118.1 1.34 >30% ±5 % ±9 %
Cl 118 mmol/L 28 114.967 2.066 1.8
Digoxin Digo 1.382/
1.48
nmol/L 10 0.048 1.4 0.41 0.192 3.09 16.09 <5% ± 25% ± 24% (<1 nmol/
L: ± 0.24%)
Digo 3.699 nmol/L 7 3.66 0.084 2.30
Aethyl-ethanol ETOH 11.3 mmol/L 15 11.253 0.767 6.82 0.16 -0.4 1.7 -4.25 <5% ± 25%
ETOH 33.2 mmol/L 14 33.35 2.69 8.07
Ferritin Ferri 12.5 ug/L 10 13.95 0.333 2.39 216.84 8.7 1726 198.39 <5% ± 25%
Ferri 416 ug/L 10 412.4 13.21 3.2
Ferri 1330 ug/L 12 1283 61.71 4.81
Folic acid Fol 6.765/
7.08
nmol/L 11 0.639 9.35 5.48 9.44 45.4 4.81 <5% ± 20%
Fol 16.91 nmol/L 11 17.381 0.604 3.48
Fol 34.731 nmol/L 12 35.185 2.26 6.42
Free Tri-iodo
thyronine
FT3 6.1/6.33 pmol/L 17 0.157 2.52 0.84 1.63 6.78 4.16 <5% 20%
FT3 25.6/
26.0
pmol/L 15 0.6588 2.658
Free Thyroxine FT4 14.3 pmol/L 16 15.82 0.54 3.41 3.84 11.27 27.13 2.41 <5% ± 3 SD ± 20%
FT4 51.6 pmol/L 16 55.69 2.42 4.35
Gentamycine Gent 3.68 umol/L 9 3.189 0.586 18.38 1.33 0 10.6 UD <5% ± 25%
Gent 9.38 umol/L 10 9.02 0.944 10.47
Gent 15.8 umol/L 11 15.891 0.879 5.53
-glutamyl
transpeptidase
GGT 46.4 U/L 17 45.65 0.61 1.34 195.30 9 1851 205.67 <5% ± 21%
GGT 206 U/L 18 205.89 2.85 1.38
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5Table 1 All test analyzed, their control values and further data used for estimation of the beta error. (Continued)
Glucose Gluc 5.09 mmol/L 19 5.07 0.092 1.81 0.86 4.6 12.6 2.74 <10% ± 0.333
mmol/L or ±
10%
± 10%
Gluc 13.2 mmol/L 18 13.232 0.273 2.06
Anti-Hepatitis A IgG HAV 18.5/
18.7/
20.5
IU/L 13 0.505 2.57 6.30 3 60 20.00 <5% 20%
HAV 32.1/
33.5/
37.1
IU/L 15 0.778 2.39
Human chorionic
gonadotropin,
Subunit
HCG-beta 9.52 mIU/mL 17 9.278 0.21 2.26 2.90 0.1 23.1 231.00 <5% ± 3 SD ± 25%
HCG-beta 38.1 mIU/mL 16 36.654 1.018 2.78
High-density
lipoprotein
HDL 1.2 mmol/L 17 1.15 0.0278 2.42 0.41 0.12 2.63 21.92 <5% ± 30%
HDL 0.74 mmol/L 18 0.6461 0.0154 2.38
Iron Iron 20 umol/L 18 20.131 0.304 1.51 2.89 1.9 27 14.21 <5% ± 20% ± 20%
Iron 29.5 umol/L 19 29.684 0.332 1.12
Potassium K 3.41 mmol/L 27 3.3661 0.08 2.38 0.50 2.3 5.11 2.22 <10% ± 0.5 mmol/L ±9 %
K 6.26 mmol/L 28 6.1757 0.0916 1.48
Lactate
Dehydrogenase
LDH 318 U/L 16 321.38 3.74 1.16 143.10 232 1199 5.17 <5% ± 20% ± 21%
LDH 497 U/L 17 501.82 4.52 0.9
Low-density
lipoprotein
LDL 2.87 mmol/L 16 2.7144 0.0669 2.46 1.03 0.89 5.97 6.71 <5% 30%
LDL 5.17 mmol/L 18 4.7817 0.0932 1.95
Lipase Lipe 55.4 U/L 18 54.28 0.67 1.23 97.68 6 808 134.67 <5% ± 24%
Lipe 89.9 U/L 18 88.33 1.88 2.13
Magnesium Mg 0.892 mmol/L 17 0.868 0.0268 3.09 0.26 0.51 1.56 3.06 <5% ± 25% ± 20%
Mg 1.68 mmol/L 17 1.7065 0.0611 3.58
Myoglobin Myo 85.2 ng/mL 11 80.107 2.025 2.53 28.68 21 170.2 8.10 <5% ± 30%
Myo 1080 ng/mL 11 1003.3 43.704 4.36
Sodium Na 121 mmol/L 27 119.79 2.92 2.44 12.69 129 153 1.19 ± 4 mmol/L ±9 %
Na 145 mmol/L 28 142.69 2.26 1.58
Pheno-barbital Phno 39.9 umol/L 10 39.9 1.91 4.79 0.80 0 8 UD <5% ± 20%
Phno 105 umol/L 11 97.55 2.46 2.52
Phno 215 umol/L 10 198.2 5.2 2.62
Phosphate Phos 1.29 mmol/L 17 1.3047 0.0194 1.49 0.20 0.62 2.06 3.32 <5% ± 15%
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5Table 1 All test analyzed, their control values and further data used for estimation of the beta error. (Continued)
Phos 2.01 mmol/L 18 2.0472 0.0321 1.57
N-terminal Brain
natriuretic peptide
Pro-BNP 131 pg/mL 12 134 5.85 4.37 1837.05 5 24489 4897.80 <5% ± 15%
Pro-BNP 4360 pg/mL 11 4944 135.5 2.74
Parathyroid-
hormone
PTH 5.7982 pmol/L 7 5.47 0.165 3.01 5.13 2.12 40.61 19.16 <5% ± 24%
PTH 20.246 pmol/L 5 19.94 0.278 1.4
PTH 86.39 pmol/L 6 87.06 1.23 1.42
Anti-Rubella IgG RubG 3.57/
3.96
IU/mL 13 0.186 4.99 50.02 0.17 500 2941.18 (1)
RubG 69.3 IU/mL 12 70.85 4.68 6.61
Anti-Rubella IgM RubM 0.23 COI 13 0.224 0.008 3.57 UD (1)
RubM 2 COI 13 1.816 0.128 7.05
Salicylate Sali 0.29 mmol/L 9 0.2667 0.0324 12.15 -0.02 -0.22 0.05 -0.23 <5% 20%
Sali 1.14 mmol/L 10 1.1335 0.0362 3.19
Sali 3.12 mmol/L 11 3.3218 0.0795 2.39
Triiodo-thyronine T3 2.46 nmol/L 16 2.34 0.179 7.66 0.30 0.541 2.47 4.57 <5% ± 3 SD 20%
T3 5.59 nmol/L 16 5.48 0.383 7
Theophyllin Theo 30.1 umol/L 9 30.44 1.88 6.18 1.38 0 11 UD <5% ± 25%
Theo 82.7 umol/L 10 83.1 2.51 3.02
Theo 171 umol/L 11 166.64 5.26 3.16
Troponin T TN-T 0.071 ug/L 13 0.073 0.003 4.11 0.31 0.01 2.54 254.00 <5% ± 24%
TN-T 2.24 ug/L 11 2.213 0.037 1.67
High-sensitivity TNT TNT-hs 0.0302 ug/L 11 0.032 0.001 3.13 0.26 0.003 2.19 730.00 <5% ± 24%
TNT-hs 2.45 ug/L 11 2.488 0.054 2.17
Tobramycin Tobr 1.79 ug/mL 9 1.8 0.071 3.94 0.03 0 0.2 UD <5% ± 25%
Tobr 4.01 ug/mL 10 3.94 0.07 1.78
Tobr 8.17 ug/mL 11 7.9 0.261 3.30
Anti-Toxo-plasma
IgG
ToxoG 0.84 IU/mL 13 0.899 0.051 5.67 77.25 0.13 617.9 4753.08 <5% 20%
ToxoG 48.1 IU/mL 13 50.549 2.93 5.80
Anti-Toxo-plasma
IgM
ToxoM 0.18 COI 13 0.14 0.015 10.71 -1 -1 1.00
ToxoM 1.78 COI 13 1.86 0.057 3.06
Total Protein TP 64.6 g/L 14 65.786 1.122 1.71 7.00 50 90 1.80 <10% ± 10% ± 15%
TP 102 g/L 15 105.23 1.05 1.00
TP 66.8 g/L 17 66.88 0.86 1.29
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5Table 1 All test analyzed, their control values and further data used for estimation of the beta error. (Continued)
TP 50.1 g/L 19 50.11 0.74 1.48
Triglycerides Trigl 1.22 mmol/L 17 1.2371 0.0126 1.02 0.74 0.67 5.21 7.78 <5% ± 25% ± 20%
Trigl 2.37 mmol/L 18 2.3711 0.0345 1.46
Transferrin Trfe 33 umol/L 13 33.154 0.689 2.08 6.30 16 47 2.94 <5% 20%
Trfe 48.9 umol/L 15 48.23 0.68 1.41
Trfe 25.1 umol/L 17 25.41 0.51 2.01
Thyroid-stimulating
hormone
TSH 1.65 uIU/mL 16 1.57 0.019 1.21 0.62 0.05 6.14 122.80 <5% ± 3 SD ± 20%
TSH 9.09 uIU/mL 15 8.57 0.114 1.33
Uric Acid UA 275 umol/L 17 276.12 2.71 0.98 75.00 93 907 9.75 <5% ± 17% ± 15%
UA 579 umol/L 18 575.11 10.53 1.83
Urea Ureal 6.84 mmol/L 17 6.9 0.094 1.36 4.15 2 39.5 19.75 <5% ± 20%
Ureal 24.4 mmol/L 18 23.967 0.387 1.61
Valproate Valp 238 umol/L 9 233.44 29.75 12.74 3.88 0 31 UD <5% ± 25%
Valp 519 umol/L 10 549 47.71 8.69
Valp 811 umol/L 11 857.45 69.14 8.06
Vanco-mycin Vanc 4.22 umol/L 10 4.59 0.468 10.2 0.18 0 1.8 UD <5% 20%
Vanc 13.5 umol/L 10 15.52 0.914 5.89
Vanc 19.6 umol/L 12 22.083 0.997 4.51
Vitamin B12 VitB12 177.858/
194.8
pmol/L 11 9.546 5.24 123.35 109.5 1124 10.26 <5% ± 20%
VitB12 392.616/
408.9
pmol/L 11 11.8 2.99
VitB12 856.08 pmol/L 12 859.636 20.04 2.33
Vitamin D VitD 55 nmol/L 6 48.36 6.93 14.33 14.71 17.78 129.3 7.27 <5% ± 20%
VitD 83.75 nmol/L 4 72.95 6.92 9.49
VitD 115.5 nmol/L 6 106.5 10.31 9.68
(1) Target value ± 2 dilutions or immune or nonimmune or positive or negative, UD = undetermined
All analyses were listed including their abbreviations used in the further tables. Their standard deviations (SD) and coefficient of variations (CV) of the controls (QC) are given. The target values of the QC material of
different analytes, as well as the measurement units, the number of QC repetitions (n), the mean, SD and CV of the QC materials are displayed. The beta error was estimated [12] using the range ratio and the
allowable biases as defined by the federal registry, the Qualab or the clinical estimate. The values used for the evaluations are displayed in bold.
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5informed consent. Their samples were immediately
anonymized after blood draw, but were decoded upon
request of the patients.
2.4 Statistics
Analyse-it for Excel (Version 2.11, 2008) was used for
the statistical analyses; the statistic procedure applied
being the Deming fit. In contrast to linear regression
analysis, the Deming procedure allows for a random
error in both test and reference measurements [10]. Per-
formed with weighed function, it accounts also for a
non-constant random error over the measurement range
[11,12]. A two sided p value of < 0.05 was considered as
significant. Coefficients of variation (CV) and standard
deviations (SD) were calculated by the Cobas 6000 soft-
ware from the quality control samples as mentioned in
table 1. These quality controls were run once a day.
2.4.1 Determination of the alpha error
The triplicates of each parameter of tubes 11 (compris-
ing all different centrifugation conditions) per patient
were compared with those of tube 22, to detect varia-
tions caused by the different gel separators. Second, test
results from all centrifugation conditions within one
tube were compared among each other. As singletons
were compared, SD or CV had to be defined using the
values of the quality control samples displayed in table
1. If the SD’s were approximately constant over the
measured range, the mean of SD’s of those quality con-
trol samples were entered. In case CV was more con-
s t a n tt h a nS D ,aw e i g h e dD e m i n gf i tw a sa p p l i e du s i n g
the means of CV’s of those quality control samples.
2.4.2 Determination of the beta error
The null hypothesis of the Deming fit tests the identity
of a test method to a reference method. The p value
defines the probability (alpha error) that the two meth-
ods deliver identical results. However, it does not deter-
mine the probability to detect a deviation of the test
method from the reference method when in fact the test
method produces aberrant or biased results. The prob-
ability to miss an existent bias (beta error) depends on
the measurement range, the allowable bias, the analytical
measurement error and the distribution of the data [12].
First, we estimated the beta error based on the tables
five and six of publication [12], using the measurement
range of our data. As allowable bias the values were pri-
marily taken from Federal registry [13], secondarily from
the Swiss regulation of Qualab [14], and thirdly by an
estimate of clinical requirement by one of the investiga-
tors (EIM) The data used are highlighted on table 1.
Second, we calculated the deviation or bias of the test
method to the reference method for the limits of refer-
ence values. The calculated bias was compared to an
allowable bias of 5%, 10% 20%, 30% or 40% and the
probability was determined that the calculated bias
exceeds the allowable bias thus indicating a significant
deviation of the test method from the reference method.
3. Results
As an illustrative example of the applied Deming
method, the scatter plot, the residual plot and the corre-
spondent numeric output of alanin-amino-transferase
(ALAT) measurements are shown in Figure 1. The
means of the triplicates of tube 11 are compared with
those of tube 22. Figure 1A shows that the identity and
the weighted Deming regression line lie closely to each
other. Figure 1B illustrates that the deviation of the
standardized residuals strongly increase in lower values,
indicating that a weighted rather than unweighted pro-
cedure should be applied. On the lower part of Figure 1,
the numerical results of the constant and proportional
bias and their p values are displayed. The constant bias
corresponding to the intercept in regression analysis
should be 0.00 ideally, the proportional bias correspond-
i n gt ot h es l o p e1 . 0 0 .T h epv a l u eo f0 . 5 7f o rt h ec o n -
stant bias and that of 0.87 for the proportional bias
indicate that neither the slope nor the intercept differs
significantly from their ideal values.
A compilation of the constant and proportional bias
over all statistical tests including all parameters and all
centrifugation conditions is displayed in additional file 1,
table S1 and an excerpt of them is illustrated in table 2.
The leftmost column shows the parameter analyzed. For
each parameter, seven statistical comparisons as dis-
played in the adjacent columns were made, resulting in
357 Deming tests (51 parameters × 7 comparisons). One
tube 22, condition 2 was excluded because several analy-
tical parameters showed aberrations that exceeded 3
standardized residuals, and we concluded that this tube
did not contain a sample of appropriate quality.
Twenty-three analytical parameters could not be evalu-
ated, as either, they were not quantitative tests or most
patient samples did not contain measurable amounts
and therefore a reliable quantitative comparison could
not be performed. They are listed as footnotes in addi-
tional file 1, table S1.
Table 2 and additional file 1, table S1 list the statistical
evaluations on all investigated parameters including the
constant bias, the proportional bias and their 95% confi-
dence intervals. The 95% confidence intervals included
the ideal values (i.e. 0.00 in constant bias or 1.00 in pro-
portional bias) for 688 of the 714 results (357 each con-
stant and proportional bias), and not included in this
interval were 26 results (18 constant, 8 proportional
biases). These data correspond to 3.6% of the 714
results, 5.0% of constant and 2.2% of proportional biases,
respectively. These percentages do not surpass the
expected 5%, as the confidence intervals include only
95% and not 100% of random variations. Moreover,
Minder et al. BMC Clinical Pathology 2011, 11:6
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Test  Method Comparison - Weighted Deming fit         
                    
   ALAT tubes 11 - 7, 10, 15  v  ALAT tubes 22 - 7, 10, 15      
Performed by   plüer       Date 18 November 2009
n 44
(used mean of X replicates vs mean of Y replicates)
Range  7.333 to 348.000
Replicates Assigned CV
Repeatability 
CV
Iterative
CV
Iterative
Mean CV
ALAT tubes 11 - 7 3 - 3.6% 3.5% 2.0%
ALAT tubes 22 - 7 3 - 3.7% 3.9% 2.2%
Allowable bias  5% 
Variance ratio  0.83
Sy|x (vertical)  0.033
Bias 95% CI SE p
Constant  0.17 -0.43 to 0.78 0.300 0.5701
Proportional  1.00 0.98 to 1.02 0.011 0.8650
H0: Constant bias = 0. H1: Constant bias 
H0: Proportional bias = 1. H1: Proportional bias 
Decision Level  Bias 95% CI SE Bias goal p
41 0.2 -0.1 to 0.6 0.19 2.1 <0.0001
H0: |Bias| %LDVJRDO+1: |Bias| < Bias goal.
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Figure 1 Deming fit. This figure shows a typical report of the Deming fit by Analyse-it for Excel: Graph A represents the scatter plot, the
regression line and indicates the identity line and the limits of a 5% bias. Graph B plots the standardized residuals. The statistical information as
discussed in the text is given as a table.
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Page 9 of 15aberrations from the ideal values were minor in these
cases, supporting the concept of pure randomness.
To further analyze the results, the distribution of the
proportional biases that should randomly vary around
the value 1.00 was studied (Figure 2). This analysis
showed that 50 percent of all proportional bias (slopes)
were located between 0.990 and 1.010, and 99% of
them were located between 0.924 and 1.086. The
extreme values were 0.90 and 1.15. The parameters
with proportional biases outside the 99% distribution
and below 0.924 were the following: sodium, bicarbo-
nate, CKMB, and those above 1.086 were bicarbonate
and CKMB. Apparently, the Deming fit did not appro-
priately estimate the slope in some of these outliers
such as CKMB. From the scatter plot, we assume that
relatively large variations in low normal values
Table 2 An illustrative excerpt of all Deming fits containing the data of some clinical chemistry and immunology
analytes.
Analysis 11:22 11 - 15:10 11 - 15:7 11 - 10:7 22 - 15:10 22 - 15:7 22 - 10:7
Bias
Const.
Prop. Bias
Const.
Prop. Bias
Const.
Prop. Bias
Const.
Prop. Bias
Const.
Prop. Bias
Const.
Prop. Bias
Const.
Prop.
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Alb -1.81 1.06 -1.86 1.06 -1.05 1.03 0.76 0.98 -0.16 1.01 0.25 0.99 0.40 0.99
Alb -4.33 to
0.71
0.99 to
1.13
-4.52 to
0.79
0.98 to
1.13
-2.55 to
0.45
0.99 to
1.07
-1.90 to
3.41
0.90 to
1.05
-2.54 to
2.23
0.94 to
1.07
-1.85 to
2.34
0.94 to
1.05
-1.83 to
2.63
0.93 to
1.04
Bili-T -0.08 1.01 -0.15 1.03 0.10 1.00 0.24 0.96 -0.04 1.01 -0.11 1.03 -0.06 1.02
Bili-T -0.18 to
0.01
0.99 to
1.02
-0.44 to
0.15
1.00 to
1.06
-0.18 to
0.38
0.96 to
1.03
0.04 to
0.44
0.94 to
0.99
-0.39 to
0.31
0.97 to
1.05
-0.52 to
0.29
0.99 to
1.07
-0.45 to
0.32
0.98 to
1.07
Ca -0.05 1.03 -0.17 1.08 -0.18 1.08 -0.01 1.00 -0.09 1.04 -0.05 1.02 0.02 0.99
Ca -0.15 to
0.04
0.99 to
1.07
-0.35 to
0.02
0.99 to
1.16
-0.33 to
-0.02
1.01 to
1.15
-0.13 to
0.11
0.95 to
1.05
-0.24 to
0.05
0.98 to
1.10
-0.20 to
0.09
0.96 to
1.09
-0.12 to
0.16
0.93 to
1.05
CK 0.15 1.00 -0.40 1.01 -1.63 1.02 -1.20 1.01 -0.98 1.03 -0.66 1.02 0.31 0.99
CK -0.19 to
0.49
0.99 to
1.01
-1.43 to
0.62
1.00 to
1.03
-2.54 to
-0.71
1.00 to
1.03
-2.89 to
0.50
0.98 to
1.03
-2.80 to
0.85
1.00 to
1.06
-1.48 to
0.17
1.00 to
1.03
-2.11 to
2.74
0.95 to
1.03
CKMB 0.23 0.94 -0.62 1.15 -0.15 1.01 0.42 0.87 -0.11 1.03 -0.10 1.01 0.01 0.98
CKMB -0.11 to
0.58
0.85 to
1.02
-2.29 to
1.05
0.74 to
1.56
-0.40 to
0.09
0.96 to
1.06
-1.06 to
1.89
0.50 to
1.24
-0.55 to
0.33
0.91 to
1.14
-0.64 to
0.44
0.87 to
1.15
-0.26 to
0.29
0.92 to
1.05
FT3 0.08 0.98 -0.18 1.05 -0.20 1.06 -0.01 1.00 -0.08 1.05 -0.24 1.07 -0.06 1.02
FT3 -0.10 to
0.26
0.93 to
1.03
-0.36 to
-0.00
1.00 to
1.11
-0.42 to
0.03
0.99 to
1.12
-0.27 to
0.24
0.93 to
1.08
-0.52 to
0.17
0.96 to
1.14
-0.67 to
0.20
0.95 to
1.18
-0.28 to
0.17
0.96 to
1.08
FT4 -0.22 1.02 -0.69 1.05 -0.76 1.05 -0.05 1.00 -0.56 1.04 0.73 1.04 -0.17 1.01
FT4 -0.63 to
0.19
0.99 to
1.04
-1.88 to
0.51
0.97 to
1.12
-2.40 to
0.89
0.95 to
1.15
-1.60 to
1.49
0.90 to
1.09
-1.45 to
0.34
0.98 to
1.09
-2.01 to
0.54
0.97 to
1.12
-1.07 to
0.74
0.95 to
1.06
GGT 0.47 1.00 -0.23 1.01 0.22 1.00 0.44 0.99 -0.15 1.01 -0.95 1.02 -0.78 1.01
GGT 0.12 to
0.83
0.98 to
1.01
-1.26 to
0.80
0.99 to
1.03
-0.22 to
0.65
0.99 to
1.02
-0.35 to
1.22
0.97 to
1.01
-1.00 to
0.70
1.00 to
1.03
-2.37 to
0.47
1.00 to
1.05
-2.53 to
0.96
0.98 to
1.04
HCGbeta 0.00 1.01 -0.01 1.01 0.00 0.98 0.00 0.97 0.00 1.01 0.00 1.02 0.00 1.01
HCGbeta -0.01 to
-0.00
0.98 to
1.03
-0.01 to
0.00
0.97 to
1.05
-0.01 to
0.00
0.94 to
1.02
0.00 to
0.01
0.92 to
1.02
-0.01 to
0.00
0.97 to
1.04
-0.01 to
0.00
0.98 to
1.05
0.00 to
0.00
0.97 to
1.05
In the second column from the left (headed 11:22), the triplicates of tubes ‘11’ are compared with the triplicates of tube 22. The constant bias (i.e. intercept) and
its 95% confidence intervals (CI) as well as the proportional bias (i.e. slope) and its confidence interval are listed. The confidence intervals for the constant bias
should include 0.00, and that of proportional bias 1.00, in order to prove the identity of the methods. The columns to the right contain identical data for
comparison, 15 versus 10 min centrifugation, 15 versus 7 and 10 versus 7 min. Further to the right, the same comparisons were made for the ‘22’-tubes. The full
list of comparisons is given as table S1 in additional files.
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Figure 2 Distribution of proportional bias: Histogram showing
the distribution of the proportional biases (Slopes). The slopes
scatter around the ideal value of 1.00. For comparison, a normal
distribution is depicted.
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Page 10 of 15influenced this estimate. In others, like bicarbonate or
sodium, the analytical imprecision combined with a
small measurement range resulted in aberration from
the 95% confidence interval.
As the values of the constant biases (intercepts)
depend on the measurement range of the analyte, no
similar analysis could be performed. Instead, we ana-
lyzed whether deviations accumulate in a certain centri-
fugation condition. The 95% confidence interval of the
constant bias did not include the ideal 0.00 value 18
times, namely in comparison between tube 11 and tube
22: twice; in tube 11 - between centrifugation condition
1 and 2: once; between condition 1 and 3: 3 times;
b e t w e e nc o n d i t i o n2a n d3 :3t i m e s ;i nt u b e2 2-
between centrifugation condition 1 and 2: 4 times;
between condition 1 and 3: twice and between condition
2 and 3: 3 times. Thus, the aberrant values did not clus-
ter under any centrifugation condition.
In six instances, both constant and proportional bias
confidence intervals did not include the ideal value.
These tests were therefore considered as potentially sig-
nificantly aberrant. These conditions were listed in table
3. In all but one case, condition 3 was involved as test
method, whereby either condition 1 or 2 were reference.
As in all instances, the confidence intervals of the pro-
portional bias and constant bias did not include the
ideal values only marginally, we concluded that these
outliers were generated only by chance. In order to
enable the readers to make his or her own adjudgment
on the significance of these deviations, the scatter plots
of all six conditions including the slopes, their confi-
dence intervals, the identity lines and the upper and
lower limits of reference where appropriate, are dis-
played in Figure 3.
The procedure that has been discussed so far, calcu-
lates the probability of identity between the test method
and the reference method (alpha error). For the purpose
of this study however, the probability of a deviation
between the two methods i.e. the beta error, is at least
as relevant as the alpha error. The use of patient sam-
ples with a sufficiently large measurement range thereby
enforced the statistical power.
The first estimate of the beta error according to the
description in paragraph 2.4.2 is listed per parameter in
table 1. All parameters except for chloride were below
the allowable limits of the bias, the problem in chloride
being the physiologically narrow range of sample values.
Second, it was tested whether a specified bias could be
detected at the limits of the reference values. As illu-
strated in Figure 1, a bias, named allowable bias on the
figure, was pre-specified and the probability calculated
that such a bias could be detected. In this example, the
upper limit of reference is 41 U/L. Five percent of 41
are 2.1 indicated on the figure as bias goal. The bias cal-
culated from the data corresponds to 0.2, which is much
smaller than 2.1. The null hypothesis that the bias is
equal or larger than the bias goal can be falsified with
high probability, which excludes a deviation with high
probability.
An illustrative sample of the 539 reference limits
tested is given in table 4 and the full information is
listed in additional file 2, table S2. 88.9% or 479 of those
tests would detect a 5% bias. Interestingly, chloride was
within this group. If the allowable bias was set to 10%,
20%, 30% and 40%, such biases would be excluded at
further 48, 8, 3, and 1 reference limits, respectively.
These figures correspond to a cumulative frequency of
97.8%, 99.2%, 99.8% and 100% of all levels tested. The
cortisol test required the highest allowable biases of all
tests for falsifying the null hypothesis, namely, once
40%, three times 30%, twice 20% and once 10%. This
indicates that the number of specimens tested were
insufficient for cortisol to exclude a bias with sufficient
certainty.
We conclude that the conditions used including the
number of measurements, the analytical range and the
analytical imprecision were sufficient to detect a beta
error with sufficient probability.
4. Discussion
Our study shows that the three centrifugation condi-
tions tested deliver identical results. Moreover, the sta-
tistical power was sufficient to exclude any major
deviation with a high probability. As mentioned before,
very few studies on the influence of different centrifuga-
tion conditions on laboratory test results have so far
been published [1-3]. In addition, a number of unpub-
lished investigations were made available to us by the
manufacturers of tubes or reagents. Our study results
do not contradict any of those studies, but rather, they
extent both the number of parameters and the test
ranges. The number of samples and the spectrum of
Table 3 Tests with confidence intervals of both
proportional and constant bias exceeding the confidence
interval and indicating a possible lack of identity
between test and reference method.
Parameter Condition Constant bias Proportional
bias
Bilirubin
direct
T 22; C 1 : C 2 0.12 (0.06 to 0.18) 0.99 (0.98 to 0.99)
Bilirubin total T 11; C 2 : C 3 0.24 (0.04 to 0.44) 0.96 (0.94 to 0.99)
Calcium T 11; C 1 : C 3 -0.18 (-0.33 to -0.02) 1.08 (1.01 to 1.15)
Folic acid T 22; C 2 : C 3 0.98 (0.24 to 1.72) 0.95 (0.91 to 0.99)
Iron T 22; C 1 : C 3 -0.22 (-0.43 to -0.02) 1.02 (1.01 to 1.03)
Transferrin T 22; C 2 : C 3 -0.84 (-1.67 to -0.02) 1.04 (1.01 to 1.06)
T: tube; C: centrifugation condition as listed under section 2: Patients,
materials and methods.
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Figure 3 The scatter plots of the Deming fits mostly aberrant from identity are depicted. The upper five diagrams (group A) show those tests with a
proportional bias outside the 99% distribution range (s. figure 2). The lower six diagrams (group B) show tests of which both proportional and constant bias did not
indicate identity between the test and the reference method, as listed in table 3.
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Page 12 of 15tests were relatively small in all preceding studies and,
as the samples mostly from healthy persons were ana-
lyzed, the measurement ranges were relatively narrow,
which altogether resulted in a relatively large beta-error.
However, no beta error was ever calculated in the pre-
vious studies despite its significance.
In this study, a total of 14690 data pairs of quantitative
clinical chemistry and immunology tests, acquired by
comparing six different conditions and three different cen-
trifugation regimens, were analyzed in 357 Deming proce-
dures. Most of the comparisons showed excellent
reproducibility indicating that the different centrifugation
Table 4 Excerpt of a list of the probabilities to detect a 5% bias with 95% certainty at the limits of the reference
ranges limited to the comparison of tubes 11 to tubes 22.
11:22 11:22
Analyse Ref. limits Bias 95% Cl SE Bias Goal p Analyse Ref. limits Bias 95% Cl SE Bias Goal p
Alb 35 0.3 0.0 to 0.5 0.12 1.8 <0.0001 HDL 0.9 0.0 0.0 to 0.0 0.00 0.0 <0.0001
Alb 58 1.6 -0.1 to 3.3 0.85 2.9 0.0683 Iron 10.6 0.1 0.0 to 0.2 0.05 0.5 <0.0001
AP 117 0.5 -0.3 to 1.2 0.39 5.9 <0.0001 Iron 28.3 0.4 0.1 to 0.8 0.17 1.4 <0.0001
ALTL 41 0.2 -0.1 to 0.6 0.19 2.1 <0.0001 K 3.5 0.0 0.0 to 0.1 0.01 0.2 <0.0001
Amy-P 53 0.0 -0.4 to 0.5 0.23 2.7 <0.0001 K 4.5 0.0 0.0 to 0.1 0.03 0.2 <0.0001
Amyl 100 1.0 0.3 to 1.7 0.35 5.0 <0.0001 LDH 288 10.1 0.9 to 19.3 4.56 14.4 0.1746
ASTL 37 0.2 -0.2 to 0.6 0.19 1.9 <0.0001 LDL 3.9 0.1 0.0 to 0.2 0.04 0.2 0.0019
Bili-D 2 0.0 0.0 to 0.1 0.03 0.1 0.0039 Lipe 60 0.5 0.0 to 1.1 0.28 3.0 <0.0001
Bili-T 20 0.0 -0.2 to 0.3 0.13 1.0 <0.0001 Mg 0.75 0.0 0.0 to 0.0 0.00 0.0 0.0138
Ca 2.02 0.0 0.0 to 0.0 0.01 0.1 <0.0001 Mg 1.25 0.0 0.0 to 0.0 0.01 0.1 <0.0001
Ca 2.6 0.0 0.0 to 0.0 0.01 0.1 <0.0001 Myo 28 0.2 -0.2 to 0.5 0.16 1.4 <0.0001
CHE 3000 -7.7 -61.1 to 45.7 26.47 150.0 <0.0001 Myo 72 -0.3 -0.9 to 0.3 0.31 3.6 <0.0001
CHE 11000 132.0 8.9 to 255.0 60.99 550.0 <0.0001 Na 135 0.1 -0.2 to 0.3 0.13 6.8 <0.0001
Chol 3.1 0.0 -0.1 to 0.0 0.03 0.2 <0.0001 Na 145 -0.5 -1.2 to 0.2 0.34 7.3 <0.0001
Chol 6.5 0.1 0.0 to 0.2 0.07 0.3 0.0011 Phos 0.87 0.0 0.0 to 0.0 0.01 0.0 <0.0001
CK 195 0.8 -0.9 to 2.5 0.82 9.8 <0.0001 Phos 1.45 0.0 0.0 to 0.0 0.01 0.1 <0.0001
CKMB 4.94 -0.1 -0.2 to 0.0 0.04 0.2 <0.0001 Pro-BNP 125 0.3 -0.9 to 1.6 0.63 6.3 <0.0001
CO2 22 -0.1 -0.4 to 0.1 0.11 1.1 <0.0001 PTH 1.59 0.0 -0.1 to 0.1 0.04 0.1 0.0435
CO2 29 -0.4 -0.7 to -0.0 0.17 1.5 <0.0001 PTH 9.33 -0.1 -0.3 to -0.0 0.05 0.5 <0.0001
Cort 82 0.9 -5.3 to 7.1 3.07 4.1 0.1509 RubG 10 0.0 -0.4 to 0.4 0.19 0.5 0.0111
Cort 958 0.3 -10.4 to 10.9 5.27 47.9 <0.0001 T3 1.3 0.0 0.0 to 0.0 0.01 0.1 <0.0001
Crea 59 0.1 -0.4 to 0.7 0.29 3.0 <0.0001 T3 3.1 0.0 -0.1 to 0.1 0.05 0.2 0.0054
Crea 104 0.0 -0.5 to 0.4 0.23 5.2 <0.0001 TN-T 0.01 0.0 0.0 to 0.0 0.00 0.0 <0.0001
CRP 10 0.1 -0.1 to 0.2 0.08 0.5 <0.0001 TNT-hs 0.014 0.0 0.0 to -0.0 0.00 0.0 <0.0001
Cl 97 0.1 -0.3 to 0.5 0.18 4.9 <0.0001 ToxoG 1 0.0 0.0 to 0.0 0.00 0.1 <0.0001
Cl 110 0.0 -0.4 to 0.4 0.20 5.5 <0.0001 TP 66 0.4 0.0 to 0.8 0.19 3.3 <0.0001
Ferri 30 -0.1 -0.4 to 0.2 0.15 1.5 <0.0001 TP 87 0.8 -0.4 to 2.0 0.59 4.4 <0.0001
Ferri 400 2.7 -0.9 to 6.2 1.77 20.0 <0.0001 Trigl 2.3 0.0 0.0 to 0.0 0.01 0.1 <0.0001
Fol 10.4 -0.1 -0.6 to 0.4 0.24 0.5 0.0484 Trfe 23 0.1 -0.1 to 0.3 0.09 1.2 <0.0001
Fol 78.9 1.6 -0.9 to 4.1 1.25 3.9 0.0343 Trfe 45 1.0 -0.2 to 2.3 0.62 2.3 0.0273
FT3 3.1 0.0 0.0 to 0.1 0.02 0.2 <0.0001 TSH 0.34 0.0 0.0 to 0.0 0.01 0.0 0.0873
FT3 6.8 -0.1 -0.2 to 0.1 0.07 0.3 0.0003 TSH 5.6 0.0 -0.1 to 0.1 0.05 0.3 <0.0001
FT4 12 0.0 -0.1 to 0.1 0.06 0.6 <0.0001 UA 420 0.9 -0.4 to 2.2 0.63 21.0 <0.0001
FT4 22 0.2 -0.1 to 0.4 0.11 1.1 <0.0001 Ureal 3 0.0 0.0 to 0.0 0.01 0.2 <0.0001
GGT 49 0.2 -0.1 to 0.6 0.18 2.5 <0.0001 Ureal 8 0.0 0.0 to 0.0 0.01 0.4 <0.0001
Gluc 3.9 0.0 -0.1 to 0.1 0.06 0.2 0.0029 VitB12 133 1.8 -2.5 to 6.1 2.15 6.7 0.0144
Gluc 5.8 0.0 0.0 to 0.1 0.04 0.3 <0.0001 VitB12 675 0.8 -7.7 to 9.3 4.20 33.8 <0.0001
HAV 20 0.0 -0.1 to 0.1 0.04 1.0 <0.0001 VitD 75 0.6 -1.0 to 2.3 0.80 3.8 0.0002
HCGbeta 2 0.0 0.0 to 0.1 0.02 0.1 0.0002
Those conditions not sensitive enough to detect a 5% bias were retested for a 10, 20, 30 or 40% bias (data not shown). The column heading Ref. limits means
limits of reference ranges. At these concentrations of the analyte, the probability was tested to detect a 5% bias. Bias: The calculated deviation of the Deming
regression line and its 95% confidence intervals (CI) and the standard error are given. Bias goal corresponds to a 5% deviation of the Deming regression line
from identity at the tested analyte concentration. The full information on all comparisons is given in supplemental Table S2.
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testing. The percentage of statistical tests outside the 95%
confidence limits was below the number expected for ran-
dom variations. Corrections of the p-values for multiple
testing could be performed, such as the Bonferroni correc-
tions. However, such procedure would increase the beta-
error that, in our opinion, is at least as informative as the
alpha-error for the purpose of our study. We preferred to
analyze those outlier data to see whether they show any
evidence of significant bias, and found evidence of random
aberration rather than any statistical significant bias. The
only way to ascertain our conclusion on the randomness
of outliers would be a repetitious examination under iden-
tical conditions to exclude or confirm those aberrant
values. We believe that we have provided sufficient data to
convince the readers on randomness of these outliers and
that the three centrifugation conditions as well as the two
different gel separators of Greiner Bio-One provided iden-
tical results on a Cobas 6000 system of Roche Diagnostics.
The beta errors calculated by two separate methods
confirmed a sufficient power of our analyses to detect
significant deviations. Thef i r s to ft h et w om e t h o d s
relied on regulatory limits either from USA or from
Switzerland supplemented with our clinical estimates.
The second one tests the biases at the limits of refer-
ence values to see whether they exceed a pre-specified
bias. The reference limits were chosen for this purpose,
as they discriminate between “normal” and “pathologi-
cal” values, and deviations at these limits would result in
“falsely normal” or “falsely pathological” results.
In addition to the quantitative tests, data from 23 qua-
litative tests or quantitative tests with little or no mea-
surable concentrations did not provide any discrepant
results. However, these tests were not statistically
evaluated.
5. Conclusions
Our study provided substantial evidences that the cen-
trifugation condition from the WHO guideline, the
conditions of 10 min centrifugation time at 2180 g
and of 7 min at 1870 g were equally effective to the
performance of the subsequent laboratory analyses.
Each of these conditions can be applied to a broad
range of clinical chemistry and immunology tests, pro-
vided that specified tubes and analytical conditions
were used (see section 2). Laboratories that have been
hitherto accommodating the WHO recommendations
are now having the possibility of reducing their centri-
fugation time to less than half of the original amount
and in turn, to reduce their overall TAT significantly.
Those laboratories that so far are reluctant to switch
from serum to heparinized plasma because of the pro-
longed centrifugation time, can now have a second
thought.
Additional material
Additional file 1: (Table S1): Deming fit results from all analytical
parameters and centrifugation conditions. The results are displayed as
outlined in the legend to table 2.
Additional file 2: (Table S2): Probabilities to detect a 5% bias with
95% certainty at the limits of the reference ranges for all
parameters and all centrifugation conditions (beta error). The results
are displayed as outlined in the legend to table 4.
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